- Market Radar
- /
- ATXI
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About ATXI
6/30/2025
Comprehensive Analysis
Financial Health
- Liquidity & Capital Structure: Avenue Therapeutics (ATXI) holds $2.6M in cash as of Q3 2024 but faces a $3.1M net loss and $9.0M negative free cash flow (2024E). Total liabilities turned negative ($-0.125B), likely due to accounting adjustments, but the company has no long-term debt. The current ratio (3.27) and quick ratio (3.18) suggest short-term liquidity is robust, but cash burn ($11.65M annualized) threatens long-term solvency without financing.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing